Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

Journal of Research in Medical Sciences

Volumn 18, Issue 7, 2013, Pages 579-581

  Roayaei, Mahnaz ^a   Ghasemi, Sedighe ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Androgen antagonist; Blood glucose; Cholesterol; Prostatic neoplasms; Triglycerides

Indexed keywords

CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL; TRIPTORELIN;

ADULT; AGED; AGING; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; FOLLOW UP; HUMAN; INSULIN SENSITIVITY; MALE; PROSTATE CANCER; TESTIS FUNCTION;

EID: 84888139027     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Saylor PJ, Smith MR. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8. Epub 2009 Mar 14.
2. FarisJE, SmithMR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010;17:240-6.
3. SprenklePC, FischH. Pathologic effects of testosterone deprivation. Curr Opin Urol 2007;17:424-30.
4. LeahyY. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy. Clin J Oncol Nurs 2008;12:771-6.
5. SaylorPJ, SmithMR. Metabolic complications of androgen deprivation therapy for prostate cancer. JUrol 2009;181:1998-2006.
6. SmithMR, LeeH, McGovernF, FallonMA, GoodeM, ZietmanAL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 2008;112:2188-94.
7. CooperbergMR, LubeckDP, MengMV, MehtaSS, CarrollPR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. JClin Oncol 2004;22:2141-9.
8. ShahinianVB, KuoYF, FreemanJL, OrihuelaE, GoodwinJS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615-24.
9. BarryMJ, DelorenzoMA, Walker-CorkeryES, LucasFL, WennbergDC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: Apopulation-based cohort study. BJU Int 2006;98:973-8.
10. D'AmicoAV, ManolaJ, LoffredoM, RenshawAA, DellaCroceA, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: Arandomized controlled trial. JAMA 2004;292:821-7.
11. Roach M 3rd, BaeK, SpeightJ, WolkovHB, RubinP, LeeRJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. JClin Oncol 2008;26:585-91.
12. NishiyamaT, KanazawaS, WatanabeR, TerunumaM, TakahashiK. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004;11:735-41.
13. SharifiN, GulleyJL, DahutWL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44.
14. SmithJC, BennettS, EvansLM, KynastonHG, ParmarM, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. JClin Endocrinol Metab 2001;86:4261-7.
15. SmithMR, LeeH, NathanDM. Insulin sensitivity during combined androgen blockade for prostate cancer. JClin Endocrinol Metab 2006;91:1305-8.
16. DockeryF, BulpittCJ, AgarwalS, DonaldsonM, RajkumarC. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci(Lond) 2003;104:195-201.
17. SmithMR, LeeH, FallonMA, NathanDM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008;71:318-22.
18. EriLM, UrdalP, BechensteenAG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. JUrol 1995;154:100-4.
19. SmithMR, FinkelsteinJS, McGovernFJ, ZietmanAL, FallonMA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603.
20. VermeulenA. Ageing, hormones, body composition, metabolic effects. World J Urol 2002;20:23-7.
21. PitteloudN, MoothaVK, DwyerAA, HardinM, LeeH, ErikssonKF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636-42.
22. TraishAM, SaadF, GuayA. The dark side of testosterone deficiency: II. Type2 diabetes and insulin resistance. JAndrol 2009;30:23-32.
23. MedlinskyJT, NapierCD, GurneyCW. The use of an antiandrogen to further investigate the erythropoietic effects of androgens. J Lab Clin Med 1969;74:85-92.